Daniel Kota, PhD, Lab
Behind the research
Stem cell research offers hope for treating many human diseases. Recent evidence has revealed that adult stem cells can ameliorate disease without the need for engraftment and differentiation. In this new therapeutic paradigm, mesenchymal stem cells (MSCs) - a subset of adult stem cells, emerge as a key player. MSCs can be isolated from virtually any adult tissue and therapies involving the use of MSCs are being considered for the treatment of various diseases including, but not limited to, heart disease, autoimmunity and diseases in the central nervous system (www.Clinicaltrials.gov). Our lab is interested in elucidating the mechanisms through which MSCs and other adult stem cells, through paracrine interactions, encourage endogenous repair and how we can harness those interactions to target congenital defects, childhood diseases, diabetes and concussions.
March 2017, Dr. Kota recently co-authored a research article in Stem Cells with Dr. Scott Olson of the University of Texas Health Science Center at Houston. This study demonstrates the therapeutic potential of mesenchymal stem cells (MSC), a type of adult stem cell, in traumatic brain injury and identifies prostaglandin E2 as a potency maker and efficacy predictor for MSC therapies in neurotrama. “Prostaglandin E2 Indicates Efficacy of Mesenchymal Stem Cells in Experimental Traumatic Brain Injury”
January 2017, Dr. Kota published an article titled “Fat and furious: harnessing the full potential of adipose-derived stromal vascular fraction” in Stem Cells Translational Medicine. The article gives and in-depth analysis of current scientific knowledge involving the clinical use of autologous stem cells isolated from adipose tissue.